Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vor Biopharma Inc
(NQ:
VOR
)
0.8048
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vor Biopharma Inc
< Previous
1
2
3
4
5
Next >
Where Vor Biopharma Stands With Analysts
March 24, 2023
Via
Benzinga
Truist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know
March 24, 2023
Via
Benzinga
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
March 23, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
February 21, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant
February 16, 2023
Via
Benzinga
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
February 16, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
January 19, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From
Vor Biopharma
Via
GlobeNewswire
Analyzing Vor Biopharma's Short Interest
January 10, 2023
Vor Biopharma's (NASDAQ:VOR) short percent of float has fallen 58.58% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 5.31% of all regular...
Via
Benzinga
Dow Edges Higher; Prometheus Biosciences Shares Jump
December 07, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday.
Via
Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
December 07, 2022
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 07, 2022
Via
Benzinga
Nasdaq Drops 75 Points; Crude Oil Down 2%
December 07, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 07, 2022
Via
Benzinga
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
December 07, 2022
From
Vor Biopharma
Via
GlobeNewswire
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
December 07, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 22, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
November 10, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 01, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
October 12, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
October 11, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
September 28, 2022
Facility to support clinical manufacturing for Vor Bio’s novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidates
From
Vor Biopharma
Via
GlobeNewswire
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
September 20, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.
Via
Benzinga
3 Biotech Stock Picks From This Wedbush Analyst
July 27, 2022
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
July 26, 2022
Upgrades
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
July 25, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 06, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 22, 2022
Via
Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
June 23, 2022
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Via
Benzinga
79 Biggest Movers From Yesterday
June 08, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.